Enliven Therapeutics (NASDAQ:ELVN) Price Target Lowered to $27.00 at Jones Trading

Enliven Therapeutics (NASDAQ:ELVN) had its price objective cut by Jones Trading from $36.00 to $27.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright lifted their price objective on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $37.25.

Enliven Therapeutics Price Performance

ELVN stock opened at $16.86 on Friday. The company has a fifty day moving average price of $18.84 and a two-hundred day moving average price of $21.74. Enliven Therapeutics has a one year low of $13.30 and a one year high of $30.03. The stock has a market cap of $827.25 million, a price-to-earnings ratio of -8.87 and a beta of 1.07.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06). Research analysts anticipate that Enliven Therapeutics will post -1.95 EPS for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other news, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction on Wednesday, May 7th. The stock was sold at an average price of $18.39, for a total transaction of $122,606.13. Following the completion of the sale, the chief operating officer now owns 309,976 shares of the company’s stock, valued at approximately $5,700,458.64. This trade represents a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock in a transaction on Monday, March 17th. The stock was sold at an average price of $20.83, for a total value of $260,375.00. Following the sale, the chief executive officer now directly owns 990,392 shares of the company’s stock, valued at $20,629,865.36. This represents a 1.25% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 76,111 shares of company stock valued at $1,493,145. 29.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC lifted its holdings in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after buying an additional 1,114 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Enliven Therapeutics by 3,058.1% during the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock worth $53,000 after buying an additional 2,630 shares in the last quarter. Quantbot Technologies LP acquired a new position in Enliven Therapeutics in the first quarter valued at about $60,000. KLP Kapitalforvaltning AS acquired a new position in Enliven Therapeutics in the fourth quarter valued at about $97,000. Finally, BNP Paribas Financial Markets acquired a new position in Enliven Therapeutics in the fourth quarter valued at about $112,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.